CMN Weekly (17 January 2025) - Your Weekly CRISPR...
CMN Weekly
Jan. 17, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Caribou Biosciences
Main focus: Next generation allogeneic CAR-T and CAR-natural killer (NK) cell therapies
Company stage: Clinical
Diseases: Non-hodgkins lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML)
Genome editing tool: CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:CRBU)
Location: Berkeley, CA, USA
Website: https://www.cariboubio.com/
Pipeline: https://www.cariboubio.com/pipeline/
Partners: Abbvie, ProMab Biotechnologies, MaxCyte
Caribou Biosciences develops novel allogeneic CAR-T and CAR-NK cell therapies. It uses CRISPR-Cas9 and CRISPR-Cas12a to knock out multiple genes, such as TRAC (endogenous T cell receptor) in healthy donor-derived T cells, and PD-1 and B2M to armor the cells. The company is testing its CB010 programme, directed towards CD19, in early clinical trials. Caribou is also developing multiple pre-clinical assets. The company is co-founded by Nobel prize winner, Jennifer Doudna.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06128044)
Sponsors:
Caribou Biosciences, Inc.
Sponsors:
Caribou Biosciences, Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, B-NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.
Sponsors:
Caribou Biosciences, Inc.
IND Enabling
Phase I
Phase II
Phase III
